2008
DOI: 10.1016/j.jvir.2007.10.011
|View full text |Cite
|
Sign up to set email alerts
|

Long-term Outcome of Uterine Artery Embolization for Symptomatic Uterine Leiomyomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

4
34
0
7

Year Published

2008
2008
2015
2015

Publication Types

Select...
5
2
1

Relationship

1
7

Authors

Journals

citations
Cited by 75 publications
(45 citation statements)
references
References 29 publications
4
34
0
7
Order By: Relevance
“…Reasons cited include the limited evidence for the long-term success of UAE, a possible impairment of fertility and premature menopause, and the radiation exposure associated with the procedure. Data from several clinical studies with follow-up periods of up to 10 years suggest that UAE provides long-term control of fibroid-related symptoms in the vast majority of patients with an acceptable reintervention rate [1][2][3][4][5]. Comparative studies have shown UAE to be at least equal to surgical treatment in clinical and economic terms [6][7][8][9][10][11].…”
Section: Introductionmentioning
confidence: 99%
“…Reasons cited include the limited evidence for the long-term success of UAE, a possible impairment of fertility and premature menopause, and the radiation exposure associated with the procedure. Data from several clinical studies with follow-up periods of up to 10 years suggest that UAE provides long-term control of fibroid-related symptoms in the vast majority of patients with an acceptable reintervention rate [1][2][3][4][5]. Comparative studies have shown UAE to be at least equal to surgical treatment in clinical and economic terms [6][7][8][9][10][11].…”
Section: Introductionmentioning
confidence: 99%
“…Die langfristige klinische Erfolgsrate liegt mit etwa 75 % deutlich darunter, wobei eine Reintervention, d. h. eine erneute Embolisation, oder eine chirurgische Therapie bei primärem Therapieversagen Erfolg verspricht [15,20,25]. Gründe für ein Therapieversagen nach Embolisation sind eine unvollständige Infarzierung, ein neues oder erneut wachsendes Myom und Beschwerden, die nicht mit Myomen assoziiert sind [17].…”
Section: Technischer Und Klinischer Erfolgunclassified
“…3d, e). Weitere Prä-diktoren für ein Therapieversagen kön-nen anhaltende Blutungsbeschwerden und Schmerzen mehr als 12 Monate nach Embolisationstherapie sowie eine inkomplette Infarzierung des dominanten Myoms sein [15].…”
Section: Technischer Und Klinischer Erfolgunclassified
“…The percentage reduction in dominant tumor volume also predict failure, defi ned as need for re-intervention [ 18 ]. Finally, when volume reduction of fi broids was in the fi rst tertile, patients more likely to be dissatisfi ed with outcome compared with women in the third tertile [ 13 ].…”
Section: Patient Selection and Prediction Of Uae Outcomementioning
confidence: 99%